• Yu Mou, Wenhao Liao, Yuchen Li, Lina Wan, Jingwen Liu, Xialing Luo, Hongping Shen, Qin Sun, Jing Wang, Jianyuan Tang, and Zhilei Wang.
• Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, P. R. China.
• Am. J. Chin. Med. 2024 Jan 1; 52 (2): 315354315-354.

AbstractLiver diseases and their related complications endanger the health of millions of people worldwide. The prevention and treatment of liver diseases are still serious challenges both in China and globally. With the improvement of living standards, the prevalence of metabolic liver diseases, including non-alcoholic fatty liver disease and alcoholic liver disease, has increased at an alarming rate, resulting in more cases of end-stage liver disease. Therefore, the discovery of novel therapeutic drugs for the treatment of liver diseases is urgently needed. Glycyrrhizin (GL), a triterpene glycoside from the roots of licorice plants, possesses a wide range of pharmacological and biological activities. Currently, GL preparations (GLPs) have certain advantages in the treatment of liver diseases, with good clinical effects and fewer adverse reactions, and have shown broad application prospects through multitargeting therapeutic mechanisms, including antisteatotic, anti-oxidative stress, anti-inflammatory, immunoregulatory, antifibrotic, anticancer, and drug interaction activities. This review summarizes the currently known biological activities of GLPs and their medical applications in the treatment of liver diseases, and highlights the potential of these preparations as promising therapeutic options and their alluring prospects for the treatment of liver diseases.

14 keywords...

hide…